Why We Should Be Willing to Pay for Hepatitis C Treatment

ARTICLE in CLINICAL GASTROENTEROLOGY AND HEPATOLOGY: THE OFFICIAL CLINICAL PRACTICE JOURNAL OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION · JUNE 2015

Impact Factor: 7.9 · DOI: 10.1016/j.cgh.2015.06.005 · Source: PubMed

READS
21

3 AUTHORS, INCLUDING:

Jagpreet Chhatwal
Harvard Medical School
49 PUBLICATIONS  187 CITATIONS

SEE PROFILE
Why We Should Be Willing to Pay for Hepatitis C Treatment
Jagpreet Chhatwal, PhD1; Qiushi Chen, BS2; Fasiha Kanwal, MD MSHS34

1Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Department of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA USA
3Houston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center
4Department of Medicine, Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX USA

Author contribution:
Study concept and design: Chhatwal, Kanwal
Drafting of manuscript: Chhatwal
Critical revision of the manuscript for important intellectual content: Chhatwal, Chen, Kanwal
Statistical analysis: Chhatwal, Chen
Interpretation of data: Chhatwal, Chen, Kanwal

Funding/Support: This study was supported in parts by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number KL2TR000146. Dr. Kanwal’s effort was supported in part by the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413).

Conflict of interest disclosures: Chhatwal received a consulting fee from Merck, Gilead and Complete HEOR Solutions, and none to report for Chen and Kanwal.

Word count: 944
Correspondence: Jagpreet Chhatwal, PhD
Department of Health Services Research, Unit 1444
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030
JChhatwal@mdanderson.org
Phone: 713-563-9455
Fax: 713-563-0020
Introduction

The launch of oral direct-acting antivirals (DAAs) to treat chronic hepatitis C virus (HCV) infection represents a significant shift in the HCV treatment paradigm. With DAAs, the sustained virologic response (SVR), i.e. efficacy of treatment has increased to more than 90%, treatment duration has decreased to as few as 8 weeks, and these regimens have no major side effects. Coupled with the updates in HCV screening guidelines, use of new DAAs could make HCV a rare disease in the next 20 years in the United States (US).\(^1\)

However, the high price of DAAs is a barrier, and has drawn criticism from patients and payers.\(^2-4\) Challenged with the budget needed to treat all HCV patients, Medicaid in at least 30 US states has restricted these treatments to patients with advanced fibrosis stage.\(^5\) With more than a million patients needing HCV treatment in the next 3–5 years in the US, the high price of DAAs could impact the budget of private payers and government. On the other hand, several recent studies have shown that these drugs provide a good value for money. Furthermore, the price of DAAs has come down since their first availability. For example, the average discounts on sofosbuvir-based regimens in 2015 are 46%\(^6\). As additional antiviral drugs become available in the near future, drug prices may drop even further.

Here we discuss the value of HCV treatment with oral DAAs considering new discounts, the importance of treating all HCV patients, and how HCV treatment costs and value compare to that of human immunodeficiency treatment (HIV) treatment.

Value of HCV Treatment

Recently published cost-effectiveness studies showed that HCV regimens based on sofosbuvir, ledipasvir, and simeprevir are cost-effective for most patients.\(^7-12\) The incremental cost-effectiveness ratios (ICERs) of these regimens (when compared to the old standard of care)
ranged from $10,000 to $284,000 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and cirrhosis status. The average ICER for all HCV patients was $55,400 per QALY. The ICERs of treatment with older therapies based on first-generation protease inhibitors, boceprevir and telaprevir, were between $17,000 and $103,000 per QALY, depending on disease stage. The ICERs of peginterferon-ribavirin (in comparison with peginterferon) were between $26,000–$64,000 per QALY. In general, the ICERs were higher in patients with early stages of liver fibrosis than in those with advanced fibrosis. Collectively, these data show that throughout its history, compared to the previous standard, overall the “new” HCV treatment cost an additional ~50,000 to 100,000 for one additional QALY gained and the DAAs are no exception.

**HCV Treatment is Now Cost-Saving**

With recent rebates on drug prices, sofosbuvir-based treatment in 2015 on an average costs 54% of the wholesale acquisition cost. Applying these discounted drug prices to our previously published simulation model, we evaluated the cost-effectiveness of DAAs. We found that compared to treatment with telaprevir / boceprevir or peginterferon-based therapies, treatment with sofosbuvir-ledipasvir regimens is cost-saving in all patients, i.e., these regimens increased QALYs and saved healthcare costs (Figure 1). This effect was most prominent in patients with genotype 1 infection. Treatment was not cost-saving, although it was cost-effective, in patients with other genotypes.

**Decreased Cost Per SVR**

Although the cost of antiviral treatment increased with the availability of new therapies, the cost-per-SVR has decreased. As shown in Figure 2, the cost of treating HCV genotype 1 with peginterferon-ribavirin, first-generation protease inhibitors, and sofosbuvir-ledipasvir (at wholesale acquisition cost) increased from $43,000 to $103,000 per patient. However, the
corresponding costs-per-SVR decreased from $213,000 to $108,000. After applying the recent discounts (46%), the cost of treatment decreased to $56,000, which is less expensive than boceprevir- and telaprevir-based therapies, and the cost-per-SVR fell to $58,000.

Health Economics of HCV versus HIV Treatment

HCV has superseded HIV as a cause of death in the US since 2007. Therefore, to put the health economics of HCV into perspective, we can compare the cost of HCV treatment with DAAs to the cost of treating HIV. The discounted lifetime cost of treating one person with HIV in the US is $315,000 in 2014 US Dollar. The corresponding cost of curing HCV with oral DAAs is $58,000—which is only 18% of the total HIV treatment cost. HIV antiretroviral treatment is cost-effective in the US; HCV treatment is cost-saving.

The total federal budget requested for HIV and AIDS in 2015 is $24.2 billion, of which $17.5 billion is allocated to HIV treatment and care. Ryan White’s AIDS Drug Assistance Program, which provides access to HIV-related medications to people with HIV, is funded at $900 million. The federal spending on HCV treatment is unknown. However, using a simulation model, we predicted that the maximum 5-year budget needed to treat all patients (by private as well as government payers) who are candidates for HCV treatment is $37 billion, ie, $7.4 billion per year. Of note, unlike HIV, HCV treatment offers a cure; therefore annual spending on HCV treatment would reduce sharply in subsequent years.

Why we should be willing to pay for HCV treatment

The cost of HCV treatment with the available oral DAAs has decreased substantially since their first availability in 2014. Furthermore, we anticipate more discounts with increased competition from other manufacturers in the near future. The overall budget needed to treat HCV is not huge and is reasonable when comparable to that of HIV. Therefore, HCV treatment should be not be
restricted to only those in advanced fibrosis stages. We have an opportunity to eliminate hepatitis C by taking appropriate and timely steps. We as a society should be willing to pay for the current HCV therapies by providing additional resources and giving attention to hepatitis C that it deserves.
References:


Figure 1. Incremental cost and effectiveness of new antiviral regimens in comparison with old standard-of-care by HCV genotype
The size of each bubble represents the relative population size needing treatment. The center of the bubble represents the incremental costs and QALYs of sofosbuvir/ledipasvir-based therapies in comparison with the old standard of care. Bubbles below the red line are cost-effective at that threshold, and bubbles below the green line are cost-saving strategies. For instance, treatment of genotype 1 patients with sofosbuvir-ledipasvir in comparison with telaprevir/boceprevir will increase QALYs and decrease costs, i.e., cost-saving strategy. Treatment of genotype 4 patients will increase both QALYs and costs, but is still cost-effective at $100,000 willingness to pay threshold. The weighted average of the results across all genotypes is cost-saving.

Figure 2. Cost and cost-per-SVR of different antiviral regimens to treat patients with hepatitis C virus genotype 1
The cost of treatment increased from peginterferon-ribavirin (PEG-RBV) to sofosbuvir/ledipasvir (SOF-LDV) in genotype 1 patients, however the corresponding costs-per-SVR decreased at the same time. Furthermore, at 46% discounts, both costs and cost-per-SVR of SOF-LDV were lower than boceprevir (BOC)- and telaprevir (TEL)-based therapies, the old standard of care.